New drug PH009-1 for EGFR-mutated lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug called PH009-1 for people with advanced non-small cell lung cancer that has a specific change (EGFR mutation). It aims to see if the drug can shrink tumors and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and willing to join the trial.
- Your lung cancer (non-small cell type) has spread or cannot be removed by surgery, and it has an EGFR mutation.
- You have at least one tumor that can be measured on a scan.
- You are able to walk and take care of yourself (ECOG score 0 or 1).
- You have not taken certain other cancer treatments recently (like other EGFR pills, chemotherapy, or immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests YK-029A as the first anti-cancer treatment instead of standard platinum chemotherapy for certain advanced non-small cell lung cancers with an EGFR exon 20 insertion mutation. It may help shrink or control tumors while improving how patients tolerate treatment.
This trial tests a new targeted drug (HS-10504) for people with advanced EGFR-mutated non-small cell lung cancer that has worsened after previous EGFR inhibitor therapy. The study aims to see if this drug can help shrink tumors or slow cancer growth.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
This trial tests a new drug (ANS014004) combined with an EGFR-targeted therapy for people with advanced non-small cell lung cancer that has an EGFR mutation. It is for those whose cancer has gotten worse after standard treatments or who cannot take them.
Hear when a new Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.